Amplifon SpACHIX:AMPM 74 EBITDA Margin % is 19.48% as of Mar. 2026, which is 12% below its 10-year median of 22.25. GuruFocus rates CHIX:AMPM with a GF Score™ of 74/100 and a GF Value™ of €26.75 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 119 Medical Distribution companies, Amplifon SpA ranks better than 92.44% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Amplifon SpA's EBITDA for the
three
months ended in Mar. 2026 was €113 Mil. Amplifon SpA's Revenue for the
three
months ended in Mar. 2026 was €580 Mil. Therefore, Amplifon SpA's EBITDA margin for the quarter that ended in Mar. 2026 was 19.48%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Amplifon SpA EBITDA Margin % Related Terms
Amplifon SpA EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Amplifon SpA's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:AMPM vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Amplifon SpA's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amplifon SpA EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Amplifon SpA's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Amplifon SpA's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amplifon SpA (CHIX:AMPM) has a EBITDA Margin % of 19.48% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Amplifon SpA and its competitors. This is 12% below median its historical median of 22.25. Over the past decade, Amplifon SpA's EBITDA Margin % has ranged from 15.85 to 24.30. According to the industry distribution chart, Amplifon SpA ranks #9 out of 119 companies in the Medical Distribution industry, placing it in the top 7.6%.
Is Amplifon SpA's EBITDA Margin % too high?
Amplifon SpA's current EBITDA Margin % of 19.48% is 12% below median its 10-year median of 22.25. Over the past 10 years, this metric has ranged from a low of 15.85 to a high of 24.30. The Medical Distribution industry median EBITDA Margin % is 4.31. Amplifon SpA's value of 19.48% is 352% above this industry median. Based on the distribution chart, Amplifon SpA ranks #9 out of 119 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Amplifon SpA has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Amplifon SpA's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Amplifon SpA ranks #9 out of 119 companies for EBITDA Margin %. This places Amplifon SpA in the top 8% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 4.31. Amplifon SpA's value of 19.48% is 352% above this benchmark. Historically, Amplifon SpA's own EBITDA Margin % has ranged from 15.85 to 24.30 over the past decade. While the company's 10-year median is 22.25 vs. the industry median of 4.31, Amplifon SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amplifon SpA's current EBITDA Margin % of 19.48% is 352% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Amplifon SpA and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amplifon SpA's current EBITDA Margin % is 19.48%, which is 12% below median its own 10-year median of 22.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplifon SpA stock overvalued right now?
Based on GuruFocus' analysis, Amplifon SpA (CHIX:AMPM) is currently considered Possible Value Trap. The stock's GF Value™ is €26.75, compared to a current price of €10.54 — trading 60.6% below its estimated fair value. The current EBITDA Margin % is 19.48%, which is 12% below median its 10-year median of 22.25 and 352% above the Medical Distribution industry median of 4.31. Amplifon SpA's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Amplifon SpA (CHIX:AMPM), the current EBITDA Margin % is 19.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amplifon SpA (CHIX:AMPM) Overvalued in 2026?
Based on GuruFocus' analysis, Amplifon SpA stock appears to be undervalued.
The current stock price of €10.54 is trading 60.6% below its estimated GF Value™ of €26.75.
GuruFocus considers Amplifon SpA to be Possible Value Trap.
Key valuation signals for CHIX:AMPM:
EBITDA Margin %: 19.48% (12% below median its 10-year median of 22.25)
GF Value™: €26.75 vs. price of €10.54 (60.6% below fair value)
Industry Position: 352% above the Medical Distribution median (#9 of 119)
No single metric tells the full story. See the CHIX:AMPM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amplifon SpA provides customizable hearing solutions and services through a distribution network of network affiliates, corporate shops, franchises, and shop-in-shops. The company operates in three segments based on geography: the Americas; Europe, the Middle East, and Africa; and Asia-Pacific. It generates the majority of its revenue in the EMEA region. It operates under a variety of brands in these regions, including Amplifon, Beter Horen, Maxtone, and Miracle-Ear.
74GF Score
Get the complete analysis for CHIX:AMPM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMPM has been successfully added to your 
